Tag: DOAC

OPTION: LAAC over OAC after ablation in patients with AF and increased stroke risk

Presented By
Prof. Oussama Wazni, Cleveland Clinic, USA
Trial
OPTION
Conference
AHA 2024
Type
Peer-reviewed article

3 February 2025 15:02

ENBALV: Edoxaban or warfarin as anticoagulant after bioprosthetic valve replacement?

Presented By
Dr Chisato Izumi, National Cerebral and Cardiovascular Center, Japan
Trial
Phase 3, ENBALV
Conference
AHA 2024
Type
Peer-reviewed article

3 February 2025 15:00

Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?

Presented By
Prof. Francis Couturaud, Brest University Hospital, France
Trial
Phase 3, RENOVE
Conference
ASH 2024
Type
Peer-reviewed article

29 January 2025 09:36

OCEANIC-AF: Asundexian inferior to apixaban for ischaemic stroke prevention in AF

Presented By
Dr Manesh Patel, Duke Clinical Research Institute, USA
Trial
Phase 3, OCEANIC-AF
Conference
ESC 2024
Type
Peer-reviewed article

7 November 2024 13:16

Abelacimab substantially lowers bleeding risk compared with rivaroxaban 

Presented By
Dr Christian Ruff, Brigham and Women’s Hospital, USA
Trial
Phase 2, AZALEA-TIMI 71
Conference
AHA 2023
Type
Peer-reviewed article

29 January 2024 15:22

NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?

Presented By
Dr Nina Becher, University of Hamburg, Germany
Trial
Phase 3, NOAH-AFNET 6
Conference
AHA 2023
Type
Peer-reviewed article

29 January 2024 15:13

ARTESIA: How useful is anticoagulation in subclinical AF? 

Presented By
Prof. Jeff Healey, McMaster University, Canada
Trial
Phase 4, ARTESIA
Conference
AHA 2023
Type
Peer-reviewed article

29 January 2024 15:08

Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension

Presented By
Dr Kazuya Hosokawa, Kyushu University, Japan
Trial
Phase 3, KABUKI
Conference
AHA 2023
Type
Peer-reviewed article

29 January 2024 14:09

Interview: Medicare’s first drug price negotiations: concerning?

Expert
Prof. Marc Bonaca, University of Colorado, USA

4 January 2024 15:06

Results of FRAIL-AF trial suggest increased bleeding risk with DOACs

Presented By
Dr Linda Joosten, University Medical Center Utrecht, the Netherlands
Trial
FRAIL-AF
Conference
ESC 2023

30 October 2023 16:04

Head-to-head: post-TAVR edoxaban not better than DAPT

Presented By
Prof. Duk-Woo Park, Asan Medical Center, Korea
Trial
Phase 4, ADAPT-TAVR
Conference
ACC 2022
Type
Peer-reviewed article

15 June 2022 14:09

2021 ESC/EACTS Guidelines on Valvular Heart Disease

Presented By
Dr Victoria Delgado, Leiden University Medical Center, the Netherlands
Conference
ESC 2021
Type
Peer-reviewed article

26 October 2021 12:18

DOACs and bleeding: the role of antidotes

Presented By
Dr Kaveshree Govender, Milpark Hospital, South Africa
Trial
RE-VERSE AD
Conference
EHRA 2021
Type
Peer-reviewed article

16 June 2021 10:26

2021 EHRA practical guide: DOACs in pre-operative and bleeding patients

Presented By
Prof. Thomas Vanassche, University Hospitals Leuven, Belgium
Conference
EHRA 2021
Type
Peer-reviewed article

15 June 2021 15:37

Surgical bleeding risk most important determinant of bleeding outcomes

Presented By
Dr Kira MacDougall, Staten Island University Hospital, USA
Trial
PAUSE
Conference
ISTH 2020
Type
Peer-reviewed article

8 September 2020 16:27

Similar bleeding rates in patients with VTE and AF treated with DOACs

Presented By
Dr Farès Moustafa, CHU Clermont Ferrand, France
Conference
ISTH 2020
Type
Peer-reviewed article

8 September 2020 16:21

Finding the sweet spot of anticoagulation in AF patients with ACS

Presented By
Prof. Renato D. Lopes, Duke University School of Medicine, USA
Trial
AUGUSTUS
Conference
ISTH 2020
Type
Peer-reviewed article

8 September 2020 14:59

Lower embryopathy risk with DOAC versus VKA during pregnancy

Presented By
Dr Jan Beyer-Westendorf, UNI-Klinikum Carl Gustav Carus Medizinische Klinik I, Germany
Conference
ISTH 2020
Type
Peer-reviewed article

8 September 2020 14:53

Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?

Presented By
Dr G.R. Hong, Yonsei University College of Medicine, South Korea
Trial
ENAVLE
Conference
ACC 2020
Type
Peer-reviewed article

7 September 2020 23:15

Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel

Presented By
Dr V. Nijenhuis, St. Antonius Hospital, the Netherlands
Trial
POPular-TAVI
Conference
ACC 2020
Type
Peer-reviewed article

7 September 2020 23:14

Apixaban offers new perspective for cancer patients in need of anticoagulation

Presented By
Prof. G. Agnelli, University of Perugia, Italy
Trial
Phase 3, CARAVAGGIO
Conference
ACC 2020
Type
Peer-reviewed article

7 September 2020 23:13

Aspirin plus DOAC is not better than a DOAC alone

Presented By
Prof. Jordan Schaefer, University of Michigan, USA
Conference
ASH 2019
Type
Peer-reviewed article

5 March 2020 19:23

Haematoma expansion and mortality in intracerebral haemorrhage after OAC

Conference
EAN 2019
Type
Peer-reviewed article

27 August 2019 12:54

Lower rates stroke/SE with DOACs in frail non-valvular AF patients

Presented By
Prof. Gregory Lip, University of Birmingham, United Kingdom
Conference
ACC 2019
Type
Peer-reviewed article

6 June 2019 15:50

Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry

Presented By
Dr Steven Deitelzweig, Ochsner Health System, USA
Conference
ACC 2019
Type
Peer-reviewed article

6 June 2019 14:55

Substantial impact of temporary interruptions of warfarin versus DOAC

Presented By
Dr Malini Madhavan, Mayo Clinic, USA
Trial
ORBIT-AF
Conference
ACC 2019
Type
Peer-reviewed article

4 June 2019 14:17

Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin

Trial
AUGUSTUS
Conference
ACC 2019
Type
Peer-reviewed article

4 June 2019 13:19
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com